These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 6232320

  • 1. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
    Takata Y, Tamura N, Fujita T.
    J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
    [Abstract] [Full Text] [Related]

  • 2. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
    Barrio E, Antón LC, Marqués G, Sánchez A, Vivanco F.
    Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of immune precipitation by complement.
    Hong K, Takata Y, Sayama K, Kozono H, Takeda J, Nakano Y, Kinoshita T, Inoue K.
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [Abstract] [Full Text] [Related]

  • 4. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
    Antón LC, Ruiz S, Barrio E, Marqués G, Sánchez A, Vivanco F.
    Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
    [Abstract] [Full Text] [Related]

  • 5. Importance of the integrity of the inter-heavy-chain disulphide bond of rabbit IgG in the activation of the alternative pathway of human complement by the F(ab')2 region of rabbit IgG antibody in immune aggregates.
    Gadd KJ, Reid KB.
    Immunology; 1981 Jan; 42(1):75-82. PubMed ID: 6780451
    [Abstract] [Full Text] [Related]

  • 6. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.
    Gadd KJ, Reid KB.
    Biochem J; 1981 May 01; 195(2):471-80. PubMed ID: 7316962
    [Abstract] [Full Text] [Related]

  • 7. C3 binds covalently to the C gamma 3 domain of IgG immune aggregates during complement activation by the alternative pathway.
    Antón LC, Alcolea JM, Sánchez-Corral P, Marqués G, Sánchez A, Vivanco F.
    Biochem J; 1989 Feb 01; 257(3):831-8. PubMed ID: 2784671
    [Abstract] [Full Text] [Related]

  • 8. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
    Joiner KA, Goldman RC, Hammer CH, Leive L, Frank MM.
    J Immunol; 1983 Nov 01; 131(5):2563-9. PubMed ID: 6355296
    [Abstract] [Full Text] [Related]

  • 9. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
    Ziccardi RJ.
    J Immunol; 1986 May 01; 136(9):3378-83. PubMed ID: 3485688
    [Abstract] [Full Text] [Related]

  • 10. Breakdown of C3 covalently bound to F(ab')2 immune complexes after complement activation by the alternative pathway.
    Antón LC, Alcolea JM, Marqués G, Sánchez-Corral P, Vivanco F.
    Complement; 1986 May 01; 3(2):53-62. PubMed ID: 3769463
    [Abstract] [Full Text] [Related]

  • 11. Stimulation of complement amplification by F(ab')(2)-containing immune complexes and naturally occurring anti-hinge antibodies, possible role in systemic inflammation.
    Lutz HU, Fumia S.
    Autoimmun Rev; 2008 Jun 01; 7(6):508-13. PubMed ID: 18558371
    [Abstract] [Full Text] [Related]

  • 12. Solubilization of immune precipitates by six isolated alternative pathway proteins.
    Fujita T, Takata Y, Tamura N.
    J Exp Med; 1981 Dec 01; 154(6):1743-51. PubMed ID: 6459396
    [Abstract] [Full Text] [Related]

  • 13. The covalent interaction of C3 with IgG immune complexes.
    Vivanco F, Muñoz E, Vidarte L, Pastor C.
    Mol Immunol; 1999 Dec 01; 36(13-14):843-52. PubMed ID: 10698338
    [Abstract] [Full Text] [Related]

  • 14. Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes.
    Zhang W, Lachmann PJ.
    Immunology; 1994 Jan 01; 81(1):137-41. PubMed ID: 8132210
    [Abstract] [Full Text] [Related]

  • 15. Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor.
    Fischer E, Appay MD, Cook J, Kazatchkine MD.
    J Immunol; 1986 Feb 15; 136(4):1373-7. PubMed ID: 2418113
    [Abstract] [Full Text] [Related]

  • 16. Activation of rat complement by soluble and insoluble rat IgA immune complexes.
    Rits M, Hiemstra PS, Bazin H, Van Es LA, Vaerman JP, Daha MR.
    Eur J Immunol; 1988 Dec 15; 18(12):1873-80. PubMed ID: 3220102
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
    Kievits F, Kijlstra A.
    Immunology; 1985 Mar 15; 54(3):449-56. PubMed ID: 3844370
    [Abstract] [Full Text] [Related]

  • 18. Clearance kinetics and organ uptake of complement-solubilized immune complexes in mice.
    Aguado MT, Mannik M.
    Immunology; 1987 Feb 15; 60(2):255-60. PubMed ID: 3817872
    [Abstract] [Full Text] [Related]

  • 19. The C(H)1 domain of IgG is not essential for C3 covalent binding: importance of the other constant domains as targets for C3.
    Muñoz E, Vidarte L, Casado MT, Pastor C, Vivanco F.
    Int Immunol; 1998 Feb 15; 10(2):97-106. PubMed ID: 9580208
    [Abstract] [Full Text] [Related]

  • 20. Human erythrocytes inhibit complement-mediated solubilization of immune complexes.
    Dorval BL, Cosio FG, Birmingham DJ, Hebert LA.
    J Immunol; 1989 Apr 15; 142(8):2721-7. PubMed ID: 2522967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.